Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma

Relapsed/Refractory multiple myeloma remains a significant clinical challenge despite a wide array of approved therapeutic agents. Immunotherapy offers an advantage in this setting. Chimeric antigen receptor (CAR) modified T-cells have transformed care for patients with hematological malignancies. CAR-T cells targeting CD-19 B-cell lymphoma cells have shown prominent activity in lymphoma and acute lymphoblastic leukemia (ALL). Recently, the CAR-T cell platform for MM demonstrated therapeutic benefit.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 17, 2020 Category: Hematology Authors: Shebli Atrash, Syed Abbas Ali, Saad Z. Usmani Tags: Review Article Source Type: research